Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:MACKNASDAQ:SPPINASDAQ:XOMANASDAQ:ZIOP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMACKMerrimack Pharmaceuticals$14.73$14.71$11.53▼$15.89$214.06M1.43111,205 shs79,779 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AXOMAXOMA$26.09+1.0%$24.56$13.48▼$27.00$303.69M0.5821,196 shs11,780 shsZIOPZIOPHARM Oncology$1.08$0.77▼$5.95$187.12M1.712.01 million shs2.13 million shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMACKMerrimack Pharmaceuticals+0.07%+0.34%-0.41%+12.02%+20.84%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%+46.85%XOMAXOMA+1.33%+6.08%+4.11%+30.73%+38.97%ZIOPZIOPHARM Oncology0.00%0.00%0.00%0.00%0.00%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AXOMAXOMA3.6371 of 5 stars3.52.00.03.02.41.70.6ZIOPZIOPHARM OncologyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMACKMerrimack PharmaceuticalsN/AN/AN/AN/ASPPISpectrum Pharmaceuticals2.00HoldN/AN/AXOMAXOMA3.00Buy$74.00183.63% UpsideZIOPZIOPHARM OncologyN/AN/AN/AN/ACurrent Analyst RatingsLatest ZIOP, MACK, SPPI, and XOMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/16/2024XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$74.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMACKMerrimack PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/ASPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87XOMAXOMA$4.76M63.80N/AN/A$7.72 per share3.38ZIOPZIOPHARM OncologyN/AN/AN/AN/A$0.58 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMACKMerrimack Pharmaceuticals-$1.18M-$0.08N/A∞N/AN/A-6.24%-6.09%5/2/2024 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/AXOMAXOMA-$40.83M-$4.04N/AN/AN/A-886.91%-25.17%-17.08%5/14/2024 (Estimated)ZIOPZIOPHARM Oncology-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/ALatest ZIOP, MACK, SPPI, and XOMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/8/2024Q4 2023XOMAXOMA-$0.36-$0.49-$0.13$0.89$1.01 million$1.83 million3/7/2024Q4 2023MACKMerrimack PharmaceuticalsN/A-$0.01-$0.01-$0.01N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AXOMAXOMAN/AN/AN/AN/AN/AZIOPZIOPHARM OncologyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMACKMerrimack PharmaceuticalsN/A43.5043.50SPPISpectrum PharmaceuticalsN/A2.712.38XOMAXOMA1.348.688.68ZIOPZIOPHARM Oncology0.183.433.43OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMACKMerrimack Pharmaceuticals63.97%SPPISpectrum Pharmaceuticals21.67%XOMAXOMA95.92%ZIOPZIOPHARM Oncology51.03%Insider OwnershipCompanyInsider OwnershipMACKMerrimack Pharmaceuticals28.87%SPPISpectrum Pharmaceuticals2.70%XOMAXOMA7.20%ZIOPZIOPHARM Oncology5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableMACKMerrimack Pharmaceuticals42614.53 million10.09 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableXOMAXOMA1311.64 million10.80 millionOptionableZIOPZIOPHARM Oncology105216.15 million204.91 millionOptionableZIOP, MACK, SPPI, and XOMA HeadlinesSourceHeadlineChildhood Cancerscuretoday.com - February 17 at 5:57 PMAlx Oncology Holdings (ALXO)investing.com - February 10 at 8:15 PMPediatric Hematology-Oncology Fellowshipbcm.edu - February 5 at 8:39 AMAlaunos Therapeutics: Other Events, Financial Statements And Exhibitscbonds.com - January 31 at 9:44 AMCG Oncology Increuters.com - January 31 at 4:43 AMOncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patientsmedscape.com - December 21 at 3:43 PMImmuno-Oncologyajmc.com - December 19 at 3:21 PMWhy Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?markets.businessinsider.com - December 18 at 8:18 AMExploring Patient-Centered Handoffs in Surgical Oncologymedscape.com - December 10 at 7:36 PMAssociation of Community Cancer Centersajmc.com - October 14 at 2:50 PMOncology News and Researchnews-medical.net - September 19 at 5:53 PMWBSPH 2024 - Oncologynewsweek.com - September 15 at 8:49 PMKris on Oncologymedscape.com - September 6 at 11:16 PMGauging Ziopharm's Chances for Positive Sarcoma Drug Trial Resultsthestreet.com - August 29 at 6:23 AMOncology Cases & Quizzesmedscape.com - August 14 at 6:15 PMZiopharm’s palifosfamide fails in first-line STS…investing.com - June 21 at 12:05 AMWeber on Oncologymedscape.com - June 19 at 2:11 PMA Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanomaascopubs.org - June 17 at 8:43 AMALX Oncology Holdings Inc Ordinary Sharesmorningstar.com - June 15 at 6:54 PMDivision of Pediatric Hematology and Oncologyslu.edu - June 13 at 3:50 PMDivision of Hematology and Medical Oncologyslu.edu - June 13 at 3:50 PMIntratumoral Cancer Therapies Global Market Report 2023finance.yahoo.com - June 9 at 1:32 PMNatural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.comarketwatch.com - May 11 at 9:52 PMVC Identifies 3 Startups That Will Shake Up the Future of Cancer Caremedcitynews.com - May 10 at 1:58 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsMerrimack PharmaceuticalsNASDAQ:MACKMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Spectrum PharmaceuticalsNASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.XOMANASDAQ:XOMAXOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.ZIOPHARM OncologyNASDAQ:ZIOPZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.